124 related articles for article (PubMed ID: 38713052)
61. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials.
Kyuno D; Takasawa A; Takasawa K; Ono Y; Aoyama T; Magara K; Nakamori Y; Takemasa I; Osanai M
Tissue Barriers; 2022 Jan; 10(1):1967080. PubMed ID: 34486479
[TBL] [Abstract][Full Text] [Related]
62. Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients.
Zhu C; Zhu L; Gu Y; Liu P; Tong X; Wu G; Zhu W; Shen W; Bao H; Ma X; Yu R; Wu X; Zhu D; Shu Y; Feng J
Front Genet; 2021; 12():608742. PubMed ID: 34594355
[TBL] [Abstract][Full Text] [Related]
63. Claudin 1 expression in basal-like breast cancer is related to patient age.
Blanchard AA; Ma X; Dueck KJ; Penner C; Cooper SC; Mulhall D; Murphy LC; Leygue E; Myal Y
BMC Cancer; 2013 May; 13():268. PubMed ID: 23721519
[TBL] [Abstract][Full Text] [Related]
64. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.
Hong JY; An JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK; Kim ST
Transl Cancer Res; 2020 May; 9(5):3367-3374. PubMed ID: 35117702
[TBL] [Abstract][Full Text] [Related]
65. Morphologic and molecular analysis of early-onset gastric cancer.
Setia N; Wang CX; Lager A; Maron S; Shroff S; Arndt N; Peterson B; Kupfer SS; Ma C; Misdraji J; Catenacci D; Hart J
Cancer; 2021 Jan; 127(1):103-114. PubMed ID: 33048355
[TBL] [Abstract][Full Text] [Related]
66. Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients.
Zhu C; Yang Q; Xu J; Zhao W; Zhang Z; Xu D; Zhang Y; Zhao E; Zhao G
J Transl Med; 2019 Apr; 17(1):109. PubMed ID: 30944005
[TBL] [Abstract][Full Text] [Related]
67. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations.
Yuan W; Zhang Z; Dai B; Wei Q; Liu J; Liu Y; Liu Y; He L; Zhou D
Cancer; 2016 Jun; 122(11):1689-96. PubMed ID: 26998897
[TBL] [Abstract][Full Text] [Related]
68. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
[TBL] [Abstract][Full Text] [Related]
69. Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma.
Kwon MJ; Kim SH; Jeong HM; Jung HS; Kim SS; Lee JE; Gye MC; Erkin OC; Koh SS; Choi YL; Park CK; Shin YK
Lab Invest; 2011 Nov; 91(11):1652-67. PubMed ID: 21844869
[TBL] [Abstract][Full Text] [Related]
70. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.
Dunlap SM; Chiao LJ; Nogueira L; Usary J; Perou CM; Varticovski L; Hursting SD
Cancer Prev Res (Phila); 2012 Jul; 5(7):930-42. PubMed ID: 22588949
[TBL] [Abstract][Full Text] [Related]
71. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival.
Bouchagier KA; Assimakopoulos SF; Karavias DD; Maroulis I; Tzelepi V; Kalofonos H; Karavias DD; Kardamakis D; Scopa CD; Tsamandas AC
In Vivo; 2014; 28(3):315-26. PubMed ID: 24815833
[TBL] [Abstract][Full Text] [Related]
72. ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer.
Gu W; Sun H; Zhang M; Mo S; Tan C; Ni S; Yang Z; Wang Y; Sheng W; Wang L
Cancer Med; 2023 Jan; 12(2):1520-1531. PubMed ID: 35864742
[TBL] [Abstract][Full Text] [Related]
73. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas.
Arnold A; Daum S; von Winterfeld M; Berg E; Hummel M; Rau B; Stein U; Treese C
Clin Transl Oncol; 2020 Dec; 22(12):2357-2363. PubMed ID: 32488802
[TBL] [Abstract][Full Text] [Related]
74. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract][Full Text] [Related]
75. Loss of claudin-3 expression induces IL6/gp130/Stat3 signaling to promote colon cancer malignancy by hyperactivating Wnt/β-catenin signaling.
Ahmad R; Kumar B; Chen Z; Chen X; Müller D; Lele SM; Washington MK; Batra SK; Dhawan P; Singh AB
Oncogene; 2017 Nov; 36(47):6592-6604. PubMed ID: 28783170
[TBL] [Abstract][Full Text] [Related]
76. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
77. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
[TBL] [Abstract][Full Text] [Related]
78. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology.
Voutsadakis IA
Cancer Treat Res Commun; 2023; 36():100746. PubMed ID: 37494750
[TBL] [Abstract][Full Text] [Related]
79. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer.
Jun KH; Kim JH; Jung JH; Choi HJ; Chin HM
Int J Surg; 2014; 12(2):156-62. PubMed ID: 24333468
[TBL] [Abstract][Full Text] [Related]
80. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue.
Jung H; Jun KH; Jung JH; Chin HM; Park WB
J Surg Res; 2011 May; 167(2):e185-91. PubMed ID: 20462599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
